- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04929041
Testando a adição de radioterapia ao tratamento usual (imunoterapia com ou sem quimioterapia) para pacientes com câncer de pulmão de células não pequenas em estágio IV que são PD-L1 negativo
Um estudo randomizado de fase II/III de terapia sistêmica baseada em imunoterapia moderna com ou sem SBRT para câncer de pulmão de células não pequenas avançado PD-L1 negativo
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Outro: Quality-of-Life Assessment
- Procedimento: Biospecimen Collection
- Biológico: Ipilimumab
- Procedimento: Computed Tomography
- Procedimento: Magnetic Resonance Imaging
- Procedimento: Echocardiography Test
- Procedimento: Positron Emission Tomography
- Biológico: Nivolumab
- Radiação: Radiation Therapy
- Procedimento: Biopsy Procedure
Descrição detalhada
PRIMARY OBJECTIVE:
I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.
SECONDARY OBJECTIVES:
I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.
II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.
III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).
QUALITY OF LIFE (QOL) OBJECTIVE:
I. To assess the health-related QOL in both treatment arms.
CORRELATIVE SCIENCE OBJECTIVE:
I. To evaluate changes in the peripheral immune microenvironment between the arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.
Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Estados Unidos, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Estados Unidos, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Estados Unidos, 92618
- City of Hope at Irvine Lennar
-
Lancaster, California, Estados Unidos, 93534
- City of Hope Antelope Valley
-
Marysville, California, Estados Unidos, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Estados Unidos, 95355
- Memorial Medical Center
-
Napa, California, Estados Unidos, 94558
- Providence Queen of The Valley
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Estados Unidos, 91030
- City of Hope South Pasadena
-
Truckee, California, Estados Unidos, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Upland, California, Estados Unidos, 91786
- City of Hope Upland
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Estados Unidos, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Estados Unidos, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Estados Unidos, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Estados Unidos, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, Estados Unidos, 80538
- Medical Center of the Rockies
-
-
Delaware
-
Millville, Delaware, Estados Unidos, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Estados Unidos, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Estados Unidos, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Estados Unidos, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Clearwater, Florida, Estados Unidos, 33756
- Morton Plant Hospital
-
Coral Gables, Florida, Estados Unidos, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Estados Unidos, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Estados Unidos, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Estados Unidos, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Estados Unidos, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Winter Haven, Florida, Estados Unidos, 33881
- Winter Haven Hospital
-
-
Georgia
-
Newnan, Georgia, Estados Unidos, 30265
- CTCA at Southeastern Regional Medical Center
-
Savannah, Georgia, Estados Unidos, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Estados Unidos, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Estados Unidos, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Estados Unidos, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Estados Unidos, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Estados Unidos, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Estados Unidos, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Estados Unidos, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Estados Unidos, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Estados Unidos, 60426
- Ingalls Memorial Hospital
-
Lake Forest, Illinois, Estados Unidos, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Estados Unidos, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Estados Unidos, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Estados Unidos, 60462
- University of Chicago Medicine-Orland Park
-
Rockford, Illinois, Estados Unidos, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Estados Unidos, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Crown Point, Indiana, Estados Unidos, 46307
- UChicago Medicine Northwest Indiana
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Estados Unidos, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Estados Unidos, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Estados Unidos, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Estados Unidos, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Estados Unidos, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Estados Unidos, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Estados Unidos, 50266
- Mercy Medical Center-West Lakes
-
West Des Moines, Iowa, Estados Unidos, 50266
- The Iowa Clinic PC
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Estados Unidos, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
-
Maine
-
Sanford, Maine, Estados Unidos, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Estados Unidos, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Estados Unidos, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Estados Unidos, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Estados Unidos, 48118
- Chelsea Hospital
-
Flint, Michigan, Estados Unidos, 48503
- Hurley Medical Center
-
Flint, Michigan, Estados Unidos, 48503
- Genesys Hurley Cancer Institute
-
Kalamazoo, Michigan, Estados Unidos, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Estados Unidos, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Estados Unidos, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Estados Unidos, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Estados Unidos, 48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw, Michigan, Estados Unidos, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Estados Unidos, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Estados Unidos, 48764
- MyMichigan Medical Center Tawas
-
West Branch, Michigan, Estados Unidos, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Estados Unidos, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Duluth, Minnesota, Estados Unidos, 55805
- Miller-Dwan Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55415
- Hennepin County Medical Center
-
Robbinsdale, Minnesota, Estados Unidos, 55422
- North Memorial Medical Health Center
-
Saint Cloud, Minnesota, Estados Unidos, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
Farmington, Missouri, Estados Unidos, 63640
- Parkland Health Center - Farmington
-
Rolla, Missouri, Estados Unidos, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Estados Unidos, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Estados Unidos, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Estados Unidos, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Estados Unidos, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Estados Unidos, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Estados Unidos, 10019
- Mount Sinai West
-
New York, New York, Estados Unidos, 10029
- Mount Sinai Hospital
-
New York, New York, Estados Unidos, 10011
- Mount Sinai Chelsea
-
New York, New York, Estados Unidos, 10075
- Lenox Hill Hospital
-
New York, New York, Estados Unidos, 10065
- Manhattan Eye Ear and Throat Hospital
-
Oswego, New York, Estados Unidos, 13126
- Upstate Cancer Center at Oswego
-
Oswego, New York, Estados Unidos, 13126
- Upstate Cancer Center Radiation Oncology at Oswego
-
Syracuse, New York, Estados Unidos, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Estados Unidos, 13215
- SUNY Upstate Medical Center-Community Campus
-
Syracuse, New York, Estados Unidos, 13210
- Upstate Cancer Center at Hill Radiation Oncology
-
Verona, New York, Estados Unidos, 13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
Raleigh, North Carolina, Estados Unidos, 27609
- Duke Cancer Center Raleigh
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44304
- Summa Health System - Akron Campus
-
-
Oklahoma
-
Lawton, Oklahoma, Estados Unidos, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Estados Unidos, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
Portland, Oregon, Estados Unidos, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin, Oregon, Estados Unidos, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Estados Unidos, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Estados Unidos, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Estados Unidos, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg, Pennsylvania, Estados Unidos, 17837
- Geisinger Medical Oncology-Lewisburg
-
Reading, Pennsylvania, Estados Unidos, 19605
- Penn State Health Saint Joseph Medical Center
-
Wilkes-Barre, Pennsylvania, Estados Unidos, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
-
Texas
-
Amarillo, Texas, Estados Unidos, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Estados Unidos, 23298
- VCU Massey Comprehensive Cancer Center
-
Tappahannock, Virginia, Estados Unidos, 22560
- VCU Health Tappahannock Hospital
-
-
Washington
-
Vancouver, Washington, Estados Unidos, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Estados Unidos, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
Walla Walla, Washington, Estados Unidos, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Ashland, Wisconsin, Estados Unidos, 54806
- Northwest Wisconsin Cancer Center
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Gundersen Lutheran Medical Center
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Estados Unidos, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Estados Unidos, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Estados Unidos, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Estados Unidos, 53188
- UW Cancer Center at ProHealth Care
-
Weston, Wisconsin, Estados Unidos, 54476
- Marshfield Medical Center - Weston
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
- PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
- For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
- Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
- No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
- No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
- No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
- >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
- No prior allogeneic tissue/solid organ transplant
- No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of non-infectious pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
- No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
- Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm A (immunotherapy, +/- chemotherapy)
Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Outros nomes:
Undergo blood sample collection
Outros nomes:
Given IV
Outros nomes:
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo PET
Outros nomes:
Given IV
Outros nomes:
Undergo tissue biopsy
Outros nomes:
|
|
Experimental: Arm B (immunotherapy, +/- chemotherapy, radiation therapy)
Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Outros nomes:
Undergo blood sample collection
Outros nomes:
Given IV
Outros nomes:
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo PET
Outros nomes:
Given IV
Outros nomes:
Undergo radiation therapy
Outros nomes:
Undergo tissue biopsy
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival (PFS) (Phase II)
Prazo: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Will be performed on an intent-to-treat (ITT) basis. |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Overall survival (OS) (Phase III)
Prazo: From randomization and death of all causes, assessed up to 5 years
|
Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status. |
From randomization and death of all causes, assessed up to 5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Qualidade de vida
Prazo: Até 5 anos
|
Até 5 anos
|
|
|
PFS
Prazo: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Assessed per Response Evaluation Criteria in Solid Tumors (RECIST). |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Objective response rate (ORR)
Prazo: Up to 5 years
|
Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates. |
Up to 5 years
|
|
Incidence of treatment-related adverse events
Prazo: Up to 5 years
|
Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test. |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Christine M Bestvina, Alliance for Clinical Trials in Oncology
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Respiratórias
- Neoplasias por Tipo Histológico
- Doenças pulmonares
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Carcinoma
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Adenocarcinoma de Pulmão
- Neoplasias Pulmonares
- Carcinoma pulmonar de células não pequenas
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Técnicas de investigação
- Terapêutica
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Procedimentos cirúrgicos, operatórios
- Técnicas citológicas
- Citodiagnóstico
- Fatores biológicos
- Fenômenos físicos
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Técnicas de diagnóstico, cirúrgico
- Técnicas de química, analíticas
- Análise de espectro
- Receptores, superfície celular
- Proteínas da membrana
- Antígenos
- Antígenos, superfície
- Biomarcadores
- Receptores, imunológicos
- Antígenos, diferenciação, linfócito T.
- Antígenos, diferenciação
- Proteínas do ponto de verificação imune
- Receptores de células T co-estimulatórias e inibitórias
- Nivolumabe
- Ipilimumabe
- Radioterapia
- Radiação
- Biópsia
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- Antígeno CTLA-4
Outros números de identificação do estudo
- NCI-2021-06042
- U10CA180821 (Concessão/Contrato do NIH dos EUA)
- NCI-2021-06042 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- A082002 (Outro identificador: CTEP)
- A082002 (Outro identificador: Alliance for Clinical Trials in Oncology)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .